CLINICAL_TRIALS
trial_result
· 2012-06-04
Clinical Trial Update: A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)
Summary
This is a completed post-marketing safety study evaluating sitagliptin (JANUVIA) for type 2 diabetes, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED | Results posted: 2012-06-04